This Plain Language Summary of Publication article (PLSP) from Future Oncology describes TASUKI-52, which studied whether adding nivolumab to chemotherapy plus bevacizumab helped 550 people with advanced nonsquamous non-small cell lung cancer. Half received the nivolumab combination, half received placebo with chemotherapy plus bevacizumab. Researchers measured survival, cancer progression, and side effects.

Visit the site using this link to read the article.

This PLSP is based on two articles called ‘Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer’ and was published in Annals of Oncology.

‘First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial’ and was published in Lung Cancer.

Visit ESMO Journals using the link to read the original article.

Visit Elsevier using the link to read the original article.